In this 46:30 audio, Danny Cohen and myself discuss why we believe $GLYC will see successful data-read outs in all studies of Uproleselan (GMI-1271). In a general sense, it makes perfect sense to be short here and predict failure. We…
Free Articles
Glycomimetics: An HSCT Vertical Play That Could Change Hematology
Glycomimetics is an HSCT Vertical Play That Could Change Hematology
How We Believe The GLYC Story Will Play Out.
After Danny and I did deeper digging, while we think secondary AML will hit, but the overall NCI denovo AML topline data will not be stat-sig. However, we also think the company will bury this as they don’t have to…
GlycoMimetics is a Bigger Deal Than Most Realize
I’ll get to the point. This company is a platform story, not just AML. Additionally, if both NCI and Company sponsored AML trials prove-out, the peak sales are close to $1B, not the $300M most wrongly calculate. why? Uproleselan is…
Why Glycomimentics is Running Up Hard+ Discord Chat Info.
I wanted to add some commentary on Glycomimetics (GLYC) as I own shares – all of them under 1 dollar as I said I would buy once prior management was removed. The prior management well, mismanaged the company’s trials -…
FPRX Article Preview
Summary Identifying undervalued developmental Biotech companies that have the potential for a turn-around story, swing trade and/or investment can often times be rewarding. Five Prime Pharma could be such a turn-around story with a deep pipeline and recent form 13D…
Immunotherapy Explained Part 3 – In Relation To Affimed
Immunotherapy Explained Part 2 – In Relation To Affimed. In part 3 here we explain and expand in the science of Immunotherapy and explain in part how $AFMD is differentiated, explain the $MRK Keytruda/AFM 13 trial plus a lot more.…
Market Commentary Fri, June 16. FED, RLYP, IONS, Brexit , Gold+ Market Forecast
Market Commentary Fri, June 16. FED, RLYP, IONS, Brexit , Gold+ Market Forecast. Yellen was a bit more dovish than we though she would be yesterday. There is not going to be a rate hike anytime soon. Subsequently, the USD…
Relypsa: How Bulls and Bears are Both Right (Archived)
You may be thinking; how can the bull and bear case on Relypsa (NASDAQ:RLYP) both be right? Before we get to this, let’s review in brief what’s been surrounding the company over the last few months. In October of last…
Affimed Science Explained – Technical Breakdown
Danny has explained Affimed’s science below, which for some may be a bit complex. Tomorrow, I will look to break down the technical explanations in more simpler terms — this is a big reason many up and coming TRUE potential…